Internal Medicine (Hematology)
The Department of Hematology of Guizhou Medical University Affiliated Hospital began in 1959 as a hematology group of Guiyang Medical College, with fewer than 20 beds, and under the leadership of hematologists such as Li Jixun, Yen Jiayi, Li Zhuogang, and Jing Bennian, the discipline has made great progress, and it became a key specialty in Guizhou Province in 1996, and completed the first allogeneic hematopoietic stem cell transplant in 1998. In 2005, under the leadership of Prof. Wang Jishi, a postdoctoral fellow in the U.S., the department has made a leap forward, and in 2010, Guizhou Hematopoietic Stem Cell Transplantation Center and Laboratory Platform were set up, which has led to a leap forward in clinical hematology diagnosis and treatment and scientific research work of the department. At present, there are 75 members in the team***, including 24 physicians, 55 nurses and 6 technicians. among the 24 physicians, 5 are senior titles, 5 are associate titles, 8 are intermediate titles, 1 is a postdoctoral fellow from the US, 9 are PhDs, 12 are masters' degree holders, 1 is a supervisor for PhD students, 7 are masters' degree holders, 1 is a chairman of the Medical Association of Guizhou Province, 1 is a vice-chairman, 3 are standing members, 7 are members, 7 are young members, and 1 is the chairman of the Guizhou Provincial Medical Association, 1 is a vice-chairman and 3 are standing members. He is a member of the Guizhou Provincial Medical Association, a chairman, a vice-chairman, a standing member, a member of the Chinese Medical Association, a member of the Chinese Medical Association, a member of the Chinese Medical Association, a member of the Chinese Medical Association, a member of the Chinese Medical Association, a member of the Chinese Society of Hematology, a member of the Chinese League Against Lymphoma, a member of the National Natural Science Foundation of China, an expert of the final examination of the key projects of the National Health and Family Planning Commission of China, an expert of the Chinese Journal of Hematology, the Journal of Leukemia - Lymphoma, the Journal of Clinical Hematology, and the Journal of Clinical Hematology. Journal, Journal of Leukemia-Lymphoma, Journal of Clinical Hematology, and 1 member of the editorial board.
The beds of this department have reached 130, including 8 beds with 100-level laminar flow, 14 transplantation beds and 108 general hematology beds, which are composed of general hematology wards, hematopoietic stem cell transplantation centers and laboratories, opening hematology outpatient clinics, special outpatient clinics and transplantation clinics, with an annual outpatient clinic capacity of more than 10,000, and nearly 3,000 inpatient hospitalizations, with the disease types focusing on hematological malignant tumors. Individualized targeted therapy and combination chemotherapy have greatly improved the complete remission rate of patients. The department carries out unrelated donor hematopoietic stem cell transplantation, haploidentical hematopoietic stem cell transplantation, non-cleared marrow hematopoietic stem cell transplantation and umbilical cord blood hematopoietic stem cell transplantation to treat hematological tumors. So far, it has completed more than 500 cases of various types of hematopoietic stem cell transplants (of which 80% are allogeneic hematopoietic stem cell transplants), and the disease-free survival period reaches 70%, and the quality of transplantation has reached the advanced level of the country. The laboratory platform of the Transplant Center is well-equipped with advanced equipment, including cytogenetics, flow cytometry and molecular biology laboratories, etc. It carries out leukemia MICM typing diagnosis, leukemia microscopic residual disease monitoring, leukemia-associated fusion gene detection, fluorescence in situ hybridization detection, HLA matching, gene sequencing, lymphocyte subpopulation detection and other projects, and has completed more than 40,000 cases of each test, which provides a good opportunity for the diagnosis, treatment, prognosis and treatment of hematological disorders. Now we have completed more than 40,000 cases of each test, which provides a reliable basis for the diagnosis, treatment and prognosis of hematological diseases, and improves the quality and efficiency of hematological diagnosis and treatment in our department, which ranks high in the performance appraisal of the hospital's core system. Our department carries out research on tumor drug resistance mechanism and reverse transcription strategy, hematopoietic stem cell transplantation relapse, GVHD prevention, etc. The relevant researches have made breakthroughs, and in recent years, we have published more than 50 SCI papers and more than 100 academic papers in core journals, and we have undertaken more than 30 funds at the national and provincial levels, and we have been awarded the second prize of the Chinese Medical Science and Technology Award, and six Scientific and Technological Progress Achievement Awards in Guizhou Province. This discipline became the first batch of master's degree-granting disciplines of hematology in China in 1981, and was approved to enroll doctoral students in the national plan in 2011, and was awarded the educational innovation base of Guizhou Institute of Hematology in 2013. This year, this discipline has added four new master's degree supervisors, and relying on the laboratory platform of the transplantation center and the rich clinical work practices of the disciplines' disease types, the teaching has been meticulous, innovative, and of high standards, and the doctoral and master's degree students have received many awards in the country and the province. The postgraduates have won many awards in the country and the province, and all of them have published 1-2 SCI papers and successfully graduated. The department aims to cultivate medical reserve force with skillful clinical diagnosis and treatment and scientific research and innovation ability, and has cultivated more than 10 doctoral postgraduates and more than 100 master's postgraduates. The department organizes the annual meeting of Guizhou Province Hematology and various hematology academic conferences, invites famous experts in the field of hematology from inside and outside the province to give lectures, exchanges, and visits, which constantly promotes the development of hematology diagnosis and treatment in our province. Prof. Wang is a senior member of ASH conference and has participated in international academic exchanges and speeches at the annual meeting of American Society of Hematology and European Society of Hematology for many times, and his academic research and attainments in the field of hematology have been recognized by international colleagues. The backbone of the young and middle-aged team of this discipline often participates in hosting and speaking at various hematology conferences held inside and outside the province, which promotes the long-term development of this discipline and expands the team's domestic influence and popularity through the international and domestic society meeting exchanges and speeches.
This study combines clinical, scientific research, teaching in one, is Guizhou Province, Guizhou Province, hematology diagnosis and treatment quality control center, Guizhou clinical key disciplines, Guizhou Province, hematology diagnosis and treatment and hematopoietic stem cell transplantation innovative talent team, the southwest region, the hospital's comprehensive strength of the third ranking of specialties, in 2016, Guizhou Provincial Health and Family Planning Commission formally approved the upgrading of our department to the Guizhou Provincial Institute of Hematology, disciplines of the exploration and innovation of the footsteps will never stop.
Postgraduate exams have questions, do not know how to summarize the content of the examination points of the examination, is not clear about the local policy of the examination registration, click on the bottom of the consulting official website, free of charge to receive review materials:/yjs/